Seminars in Hematology
Volume 45, Issue 4 , Pages 242-249 , October 2008

Anemia of Aging: The Role of Chronic Inflammation and Cancer

  • Luigi Ferrucci

      Affiliations

    • Longitudinal Studies Section, Clinical Research Branch, National Institute on Aging, Baltimore, MD
    • Corresponding Author InformationAddress correspondence to Luigi Ferrucci, MD, Longitudinal Studies Section, Clinical Research Branch, National Institute on Aging, 3001 S Harbor St, Baltimore, MD 21225
    • ,
  • Lodovico Balducci

      Affiliations

    • Departments of Oncology and Medicine, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL

References 

  1. Patel KV, Guralnik JM. Epidemiology of Anemia in Older Adults. Cambridge, UK: Cambridge University Press; 2008;
  2. Culleton BF, Manns BJ, Zhang J, Tonelli M, Klarenbach S, Hemmelgarn BRL. Impact of anemia on hospitalization and mortality in older adults. Blood. 2006;107:3841–3846
  3. Penninx BW. Anemia and Functional Decline. New York, NY: Springer; 2007;
  4. Atti AR, Palmer K, Volpato S, Zuliani G, Winblad B, Fratiglioni L. Anaemia increases the risk of dementia in cognitively intact elderly. Neurobiol Aging. 2006;27:278–284
  5. Penninx BW, Pluijm SM, Lips P, Woodman R, Miedema K, Guralnik JM, et al. Late-life anemia is associated with increased risk of recurrent falls. J Am Geriatr Soc. 2005;53:2106–2111
  6. Go AS, Yang J, Ackerson LM, Lepper K, Robbins S, Massie BM, et al. Hemoglobin level, chronic kidney disease, and the risks of death and hospitalization in adults with chronic heart failure: The Anemia in Chronic Heart Failure: Outcomes and Resource Utilization (ANCHOR) study. Circulation. 2006;113:2713–2723
  7. Wu WC, Rathore SS, Wang Y, Radford MJ, Krumholz HM. Blood transfusion in elderly patients with acute myocardial infarction. N Engl J Med. 2001;345:1230–1236
  8. Ania BJ, Suman VJ, Fairbanks VF, Rademacher DM, Melton LJ. Incidence of anemia in older people: An epidemiologic study in a well defined population. J Am Geriatr Soc. 1997;45:825–831
  9. Guralnik JM, Eisenstaedt RS, Ferrucci L, Klein HG, Woodman RC. Prevalence of anemia in persons 65 years and older in the United States: Evidence for a high rate of unexplained anemia. Blood. 2004;104:2263–2268
  10. Ferrucci L, Guralnik JM, Bandinelli S, Semba RD, Lauretani F, Corsi A, et al. Unexplained anaemia in older persons is characterised by low erythropoietin and low levels of pro-inflammatory markers. Br J Haematol. 2007;136:849–855
  11. Ferrucci L, Guralnik JM, Woodman RC, Bandinelli S, Lauretani F, Corsi AM, et al. Proinflammatory state and circulating erythropoietin in persons with and without anemia. Am J Med. 2005;118:1288
  12. Smith RE, Aapro MS, Ludwig H, Pinter T, Smakal M, Ciuleanu TE, et al. Darbepoetin alpha for the treatment of anemia in patients with active cancer not receiving chemotherapy or radiotherapy: Results of a phase III, multicenter, randomized, double-blind, placebo-controlled study. J Clin Oncol. 2008;26:1040–1050
  13. Thomas G, Ali S, Hoebers FJ, Darcy KM, Rodgers WH, Patel M, et al. Phase III trial to evaluate the efficacy of maintaining hemoglobin levels above 12.0 g/dL with erythropoietin vs above 10.0 g/dL without erythropoietin in anemic patients receiving concurrent radiation and cisplatin for cervical cancer. Gynecol Oncol. 2008;108:317–325
  14. FDA receives new data on risks of anemia drugs. FDA News. 2008;
  15. Overgaard J, Hoff C, Hansen HS. Randomized study of the importance of novel erythropoiesis stimulating protein (Aranesp) for the effect of radiotherapy in patients with primary squamous cell carcinoma of the head and neck (HNSCC) (The Danish Head and Neck Cancer Group DAHNCA 10 rand). Eur J Cancer suppl. 2007;5:7;(abstr 6LB)
  16. Wright JR, Ung YC, Julian JA, Pritchard KI, Whelan TJ, Smith C, et al. Randomized, double-blind, placebo-controlled trial of erythropoietin in non-small-cell lung cancer with disease-related anemia. J Clin Oncol. 2007;25:1027–1032
  17. Leyland-Jones B, Semiglazov V, Pawlicki M, Pienkowski T, Tjulandin S, Manikhas G, et al. Maintaining normal hemoglobin levels with epoetin alfa in mainly nonanemic patients with metastatic breast cancer receiving first-line chemotherapy: A survival study. J Clin Oncol. 2005;23:5960–5972
  18. Hedenus M, Adriansson M, San Miguel J, Kramer MR, Juvonen E, Taylor K, et al. Darbepoetin Alfa 20000161 Study Group (Efficacy and safety of darbepoetin alfa in anaemic patients with lymphoproliferative malignancies: A randomized, double-blind, placebo-controlled study). Br J Haematol. 2003;122:394–403
  19. Henke M, Laszig R, Rube C, Schafer U, Hasse KD, Schilcher B, et al. Erythropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy: Randomised, double-blind, placebo-controlled trial. Lancet. 2003;362:1255–1260
  20. Walston J, Hadley EC, Ferrucci L, Guralnik JM, Newman AB, Studenski SA, et al. Research agenda for frailty in older adults: Toward a better understanding of physiology and etiology: summary from the American Geriatrics Society/National Institute on Aging Research Conference on Frailty in Older Adults. J Am Geriatr Soc. 2006;54:991–1001
  21. Ruggiero C, Ferrucci L. The endeavor of high maintenance homeostasis: Resting metabolic rate and the legacy of longevity. J Gerontol A Biol Sci Med Sci. 2006;61:466–471
  22. Chaves PH, Semba RD, Leng SX, Woodman RC, Ferrucci L, Guralnik JM, et al. Impact of anemia and cardiovascular disease on frailty status of community-dwelling older women: The Women's Health and Aging Studies I and II. J Gerontol A Biol Sci Med Sci. 2005;60:729–735
  23. Woodman R, Ferrucci L, Guralnik J. Anemia in older adults. Curr Opin Hematol. 2005;12:123–128
  24. Chahal HS, Drake WM. The endocrine system and ageing. J Pathol. 2007;211:173–180
  25. Ferrucci L, Maggio M, Bandinelli S, Basaria S, Lauretani F, Ble A, et al. Low testosterone levels and the risk of anemia in older men and women. Arch Intern Med. 2006;166:1380–1388
  26. Fein HG, Rivlin RS. Anemia in thyroid diseases. Med Clin North Am. 1975;59:1133–1145
  27. Ferrucci L, Corsi A, Lauretani F, Bandelli S, Bartali B, Taubb DD, et al. The origins of age-related proinflammatory state. Blood. 2005;105:2294–2299
  28. Yaffe K, Kanaya A, Lindquist K, Simonsick EM, Harris T, Shorr RI, et al. The metabolic syndrome, inflammation, and risk of cognitive decline. JAMA. 2004;292:2237–2242
  29. Cesari M, Penninx BW, Newman AB, Kritchevsky SB, Nicklas BJ, Sutton-Tyrell K, et al. Inflammatory markers and onset of cardiovascular events: Results from the Health ABC study. Circulation. 2003;108:2317–2322
  30. Cesari M, Penninx BW, Pahor M. Inflammatory markers and physical performance in older persons: The InCHIANTI study. J Gerontol A Biol Sci Med Sci. 2004;59:242–248
  31. Alley DE, Crimmins E, Bandeen-Roche K, Guralnik J, Ferrucci L. Three-year change in inflammatory markers in elderly people and mortality: The Invecchiare in Chianti study. J Am Geriatr Soc. 2007;55:1801–1807
  32. Ferrucci L, Harris TB, Guralnik JM, Tracy RP, Corti MC, Cohen HJ, et al. Serum IL-6 level and the development of disability in older persons. J Am Geriatr Soc. 1999;47:639–646
  33. Lipschitz DA. The anemia of chronic disease. J Am Geriatr Soc. 1990;38:1258–1264
  34. van der Putten K, Braam B, Jie KE, Gaillard CA. Mechanisms of disease: Erythropoietin resistance in patients with both heart and kidney failure. Nat Clin Pract Nephrol. 2008;4:47–57
  35. Scharte M, Fink MP. Red blood cell physiology in critical illness. Crit Care Med. 2003;31(suppl):S651–S657
  36. Eisenstaedt R, Penninx BW, Woodman RC. Anemia in the elderly: Current understanding and emerging concepts. Blood Rev. 2006;20:213–216
  37. Ganz T. Hepcidin, a key regulator of iron metabolism and mediator of anemia of inflammation. Blood. 2003;102:783–788
  38. Nemeth E, Rivera S, Gabayan V, Keller C, Pedersen BK, Ganz T. IL-6 mediates hypoferremia of inflammation by inducing the synthesis of the iron regulatory hormone hepcidin. J Clin Invest. 2004;113:1271–1276
  39. Lang KS, Lang PA, Bauer C, Duranton C, Wider T, Huber SM, et al. Mechanisms of suicidal erythrocyte death. Cell Physiol Biochem. 2005;15:195–202
  40. Roy CN, Andrews NC. Anemia of inflammation: The hepcidin link. Curr Opin Hematol. 2005;12:107–111
  41. Nemeth E, Valore EV, Territo M, Schiller G, Lichtenstein A, Ganz T. Hepcidin, a putative mediator of anemia of inflammation, is a type II acute-phase protein. Blood. 2003;101:2461–2463
  42. Denny SD, Kuchibhatla MN, Cohen HJ. Impact of anemia on mortality, cognition, and function in community-dwelling elderly. Am J Med. 2006;119:327–334
  43. Landi F, Russo A, Danese P, Liperoti R, Barillaro C, Bernabei R, et al. Anemia status, hemoglobin concentration, and mortality in nursing home older residents. J Am Med Dir Assoc. 2007;8:322–327
  44. Zakai NA, Katz R, Hirsch C, Shlipak MG, Chaves PH, Newman AB, et al. A prospective study of anemia status, hemoglobin concentration, and mortality in an elderly cohort: The Cardiovascular Health Study. Arch Intern Med. 2005;165:2214–2220
  45. Balducci L, Ershler WB. Cancer and ageing: A nexus at several levels. Nat Rev Cancer. 2005;5:655–662
  46. Benson K, Balducci L. Anemia and Cancer. New York, NY: Springer; 2007;
  47. Prosnitz RG, Yao B, Farrell CL, Clough R, Brizel DM. Pretreatment anemia is correlated with the reduced effectiveness of radiation and concurrent chemotherapy in advanced head and neck cancer. Int J Radiat Oncol Biol Phys. 2005;61:1087–1095
  48. Grogan M, Thomas GM, Melamed I, Wong FL, Pearcey RG, Joseph PK, et al. The importance of hemoglobin levels during radiotherapy for carcinoma of the cervix. Cancer. 1999;86:1528–1536
  49. Extermann M, Chen H, Cantor AB, Corcoran MB, Meyer J, Grendys E, et al. Predictors of tolerance to chemotherapy in older cancer patients: A prospective pilot study. Eur J Cancer. 2002;38:1466–1473
  50. Schrijvers D, Highley M, De Bruyn E, Van Oosterom AT, Vermorken JB. Role of red blood cells in pharmacokinetics of chemotherapeutic agents. Anticancer Drugs. 1999;10:147–153
  51. Luciani A, Balducci L, Extermann M: Fatigue may be a cause of functional dependence in older cancer patients. Am J Clin Oncol (in press)
  52. Tralongo P, Respini D, Ferrau F. Fatigue and aging. Crit Rev Oncol Hematol. 2003;48(suppl):S57–S64
  53. Bennett CL, Silver SM, Djulbegovic B, Samaras AT, Blau CA, Gleason KJ, et al. Venous thromboembolism and mortality associated with recombinant erythropoietin and darbepoetin administration for the treatment of cancer-associated anemia. JAMA. 2008;299:914–924
  54. Curt GA, Breitbart W, Cella D, Groopman JE, Horning SJ, Itri LM, et al. Impact of cancer-related fatigue on the lives of patients: New findings from the Fatigue Coalition. Oncologist. 2000;5:353–360
  55. Aapro M, Leonard RC, Barnadas A, Marangolo M, Untch M, Malamos N, et al. Effect of once-weekly epoetin beta on survival in patients with metastatic breast cancer receiving anthracycline- and/or taxane-based chemotherapy: Results of the Breast Cancer-Anemia and the Value of Erythropoietin (BRAVE) study. J Clin Oncol. 2008;26:592–598
  56. Littlewood TJ, Bajetta E, Nortier JW, Vercammen E, Rapoport B. Effects of epoetin alfa on hematologic parameters and quality of life in cancer patients receiving nonplatinum chemotherapy: Results of a randomized, double-blind, placebo-controlled trial. J Clin Oncol. 2001;19:2865–2874
  57. Vansteenkiste J, Pirker R, Massuti B, Barata F, Font A, Fiegl M, et al. Aranesp 980297 Study Group (Double-blind, placebo-controlled, randomized phase III trial of darbepoetin alfa in lung cancer patients receiving chemotherapy). J Natl Cancer Inst. 2002;94:1211–1220
  58. Auerbach M, Ballard H, Trout JR, McIlwain M, Ackerman A, Bahrain H, et al. Intravenous iron optimizes the response to recombinant human erythropoietin in cancer patients with chemotherapy-related anemia: A multicenter, open-label, randomized trial. J Clin Oncol. 2004;22:1301–1307
  59. Nemeth E, Ganz T. Iron and Aging. Cambridge, UK: Cambridge University Press; 2008;
  60. Bohlius J, Wilson J, Seidenfeld J, Piper M, Schwarner G, Sandercock J, et al. Recombinant human erythropoietins and cancer patients: Updated meta-analysis of 57 studies including 9353 patients. J Natl Cancer Inst. 2006;98:708–714
  61. Henke M, Mattern D, Pepe M, Bezay C, Weissenberger C, Werner M, et al. Do erythropoietin receptors on cancer cells explain unexpected clinical findings?. J Clin Oncol. 2006;24:4708–4713
  62. Crawford J. Erythropoietin: High profile, high scrutiny. J Clin Oncol. 2007;25:1021–1023
  63. Crawford J, Henry DH, Vansteenkiste J, Ludwig H, Lillie T, Fleishman A, et al. The effect of hemoglobin (hb) level at ESA initiation on outcomes in cancer patients (pts) with chemotherapy-induced anemia (CIA): A patient-based meta-analysis from 6 randomized, placebo-controlled trials (RCTS) of darbepoetin alfa (DA). Blood. 2007;110:3780
  64. Grote T, Yeilding AL, Castillo R, Butler D, Fishkin E, Henry DH, et al. Efficacy and safety analysis of epoetin alfa in patients with small-cell lung cancer: A randomized, double-blind, placebo-controlled trial. J Clin Oncol. 2005;23:9377–9386
  65. Rizzo JD, Somerfield MR, Hagerty KL, Seidenfeld J, Bohlius J, Bennett CL, et al. American Society of Clinical Oncology; American Society of Hematology (Use of epoetin and darbepoetin in patients with cancer: 2007 American Society of Clinical Oncology/American Society of Hematology clinical practice guideline update). J Clin Oncol. 2008;26:132–149

PII: S0037-1963(08)00103-0

doi: 10.1053/j.seminhematol.2008.06.001

Seminars in Hematology
Volume 45, Issue 4 , Pages 242-249 , October 2008

Article Tools

* Image Usage & Resolution